Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Hadaschik

Showing results (171-180 of 269) with videos related to

Pageof 27
Sort By:
European Radiology|December 1, 2023
Recurrent prostate cancer: combined role for MRI and PSMA-PET in <sup>68</sup>Ga-PSMA-11 PET/MRIKai Jannusch, Nils Martin Bruckmann, Janna Morawitz, et al.
Clinical Nuclear Medicine|October 26, 2023
PSMA Radioligand Therapy in Prostate Cancer: Where Are We and Where Are We Heading?Ludmila Santiago Almeida, Elba Cristina Sá de Camargo Etchebehere, Irene García Megías, et al.
International Journal of Cancer|September 18, 2021
A quantitative polymerase chain reaction based method for molecular subtype classification of urinary bladder cancer-Stromal gene expressions show higher prognostic values than intrinsic tumor genesCsilla Olah, Christina Hahnen, Nikolett Nagy, et al.
Scientific Reports|June 21, 2026
UCA1 copy number gain in serum cfDNA predicts next-generation antiandrogen resistance in metastatic castration-resistant prostate cancerAnita Csizmarik, Áron Soós, Melinda Váradi, et al.
Radiology|July 11, 2023
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate CancerAndrei Gafita, Loïc Djaileb, Isabel Rauscher, et al.
BJU International|April 22, 2020
Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancerTibor Szarvas, Anita Csizmarik, Tamás Fazekas, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 6, 2021
High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranosticsClaudia Kesch, Leubet Yirga, Katharina Dendl, et al.
World Journal of Urology|June 12, 2014
Evolution of repeat prostate biopsy strategies incorporating transperineal and MRI-TRUS fusion techniquesTimur H Kuru, Kasra Saeb-Parsy, Andrea Cantiani, et al.
Cancers|June 2, 2021
High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor TherapyUlrich Krafft, Csilla Olah, Henning Reis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 2, 2024
Safety and Efficacy of Extended Therapy with [<sup>177</sup>Lu]Lu-PSMA: A German Multicenter StudyRobert Seifert, Tugce Telli, Constantin Lapa, et al.
Pageof 27

Showing results (171-180 of 269) with videos related to

Sort By:
Pageof 27
European Radiology|December 1, 2023
Recurrent prostate cancer: combined role for MRI and PSMA-PET in <sup>68</sup>Ga-PSMA-11 PET/MRIKai Jannusch, Nils Martin Bruckmann, Janna Morawitz, et al.
Clinical Nuclear Medicine|October 26, 2023
PSMA Radioligand Therapy in Prostate Cancer: Where Are We and Where Are We Heading?Ludmila Santiago Almeida, Elba Cristina Sá de Camargo Etchebehere, Irene García Megías, et al.
International Journal of Cancer|September 18, 2021
A quantitative polymerase chain reaction based method for molecular subtype classification of urinary bladder cancer-Stromal gene expressions show higher prognostic values than intrinsic tumor genesCsilla Olah, Christina Hahnen, Nikolett Nagy, et al.
Scientific Reports|June 21, 2026
UCA1 copy number gain in serum cfDNA predicts next-generation antiandrogen resistance in metastatic castration-resistant prostate cancerAnita Csizmarik, Áron Soós, Melinda Váradi, et al.
Radiology|July 11, 2023
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate CancerAndrei Gafita, Loïc Djaileb, Isabel Rauscher, et al.
BJU International|April 22, 2020
Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancerTibor Szarvas, Anita Csizmarik, Tamás Fazekas, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 6, 2021
High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranosticsClaudia Kesch, Leubet Yirga, Katharina Dendl, et al.
World Journal of Urology|June 12, 2014
Evolution of repeat prostate biopsy strategies incorporating transperineal and MRI-TRUS fusion techniquesTimur H Kuru, Kasra Saeb-Parsy, Andrea Cantiani, et al.
Cancers|June 2, 2021
High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor TherapyUlrich Krafft, Csilla Olah, Henning Reis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 2, 2024
Safety and Efficacy of Extended Therapy with [<sup>177</sup>Lu]Lu-PSMA: A German Multicenter StudyRobert Seifert, Tugce Telli, Constantin Lapa, et al.
Pageof 27